=== МЕТАДАННЫЕ ===
{
  "original_filename": "Reassessing the First Step_ Lessons From ES-BempedACS and the Era of Multi-Mechanism LDL-C Lowering _ Circulation.html",
  "converted_date": "2026-01-31T14:51:23.268566",
  "file_size_bytes": 384381,
  "original_format": "html",
  "document_type": "Articles",
  "source_folder": "Articles",
  "full_path": "00_RAW_CARDIOLOGY/Articles/Reassessing the First Step_ Lessons From ES-BempedACS and the Era of Multi-Mechanism LDL-C Lowering _ Circulation.html"
}

=== СОДЕРЖАНИЕ ===
Reassessing the First Step: Lessons From ES-BempedACS and the Era of Multi-Mechanism LDL-C Lowering | Circulation
Skip to main content
Advertisement
Become a memberVolunteerDonate
JournalsBrowseCollectionsSubjectsAHA Journal PodcastsTrend WatchResourcesCMEAHA Journals @ MeetingsJournal MetricsEarly Career ResourcesInformationFor AuthorsFor ReviewersFor SubscribersFor International UsersAlerts
Shopping cart with
0
item
Cart
Search
Sign in
REGISTER
Quick Search in JournalsEnter search termQuick Search anywhereEnter search termQuick search in CitationsJournalYearVolumeIssuePageSearching:This JournalThis JournalAnywhereCitation
Advanced Search
Search
navigate the sidebar menu
Sign in
REGISTER
Quick Search anywhereEnter search term
Publications
Arteriosclerosis, Thrombosis, and Vascular Biology
Circulation
Current Issue
Archive
Journal Information
About Circulation
Author
Instructions
Editorial
Board
Information for Advertisers
Features
Circ On The Run
Podcast
Special
Issues
Circulation at
Major Meetings
Supplements
Hospitals of
History
Circulation Research
Hypertension
Stroke
Journal of the American Heart Association
Circulation: Arrhythmia and Electrophysiology
Circulation: Cardiovascular Imaging
Circulation: Cardiovascular Interventions
Circulation: Population Health and Outcomes
Circulation: Genomic and Precision Medicine
Circulation: Heart Failure
Stroke: Vascular and Interventional Neurology
Annals of Internal Medicine: Clinical Cases
Information
For Authors
For Reviewers
For Subscribers
For International Users
Submit & Publish
Submit to the AHA
Editorial Policies
Open Science
Value of Many Voices
Publishing with the AHA
Open Access Information
Resources
AHA Journals CME
AHA Journals @ Meetings
Metrics
AHA Journals Podcast Network
Early Career Resources
Trend Watch
Professional Heart Daily
AHA Newsroom
Current Issue
Archive
Journal Information
About Circulation
Author
Instructions
Editorial
Board
Information for Advertisers
Features
Circ On The Run
Podcast
Special
Issues
Circulation at
Major Meetings
Supplements
Hospitals of
History
Submit
Reference #1
EditorialOriginally Published 20 January 2026Reassessing the First Step: Lessons From ES-BempedACS and the Era of Multi-Mechanism LDL-C LoweringJelani K. Grant, MD, MHS https://orcid.org/0000-0001-8034-2366, and Thorsten M. Leucker, MD, PhD https://orcid.org/0000-0003-2569-6617 tleucke1@jhmi.eduAuthor Info & AffiliationsCirculationVolume 153, Number 3https://doi.org/10.1161/CIRCULATIONAHA.125.077771
20MetricsTotal Downloads20Last 12 Months20View all metrics
Track CitationsAdd to favorites
Get AccessContentsReferenceseLettersInformation & AuthorsMetrics & CitationsGet AccessReferencesFiguresTablesMediaShareVIEW RELATED ARTICLE:Triple Versus Dual Lipid-Lowering Therapy in Acute Coronary Syndrome: The ES-BempedACS Randomized Clinical TrialGet full access to this articleView all available purchase options and get full access to this article.Get AccessAlready a Subscriber? Sign in as an individual or via your institutionReferences1.Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36:1163–1170. doi: 10.1093/eurheartj/ehu505CrossrefPubMedGoogle Scholar2.Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Covington AM, DePalma SM, Minissian MB, Orringer CE, Smith SC, Waring AA, et al; Writing Committee. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. J Am Coll Cardiol. 2022;80:1366–1418. doi: 10.1016/j.jacc.2022.07.006CrossrefPubMedGoogle Scholar3.Mach F, Koskinas KC, Roeters van Lennep JE, Tokgözoğlu L, Badimon L, Baigent C, Benn M, Binder CJ, Catapano AL, De Backer GG, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46:4359–4378. doi: 10.1093/eurheartj/ehaf190CrossrefPubMedGoogle Scholar4.Sarraju A, Yan X, Huang Q, Dudum R, Palaniappan L, Rodriguez F. Patterns and gaps in guideline-directed statin use for atherosclerotic cardiovascular disease by race and ethnicity. Am J Prev Cardiol. 2024;17:100647. doi: 10.1016/j.ajpc.2024.100647CrossrefPubMedGoogle Scholar5.Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–e1143. doi: 10.1161/CIR.0000000000000625CrossrefPubMedGoogle Scholar6.Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019;41:111–188. doi: 10.1093/eurheartj/ehz455CrossrefGoogle Scholar7.Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, et al; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–2397. doi: 10.1056/NEJMoa1410489CrossrefPubMedGoogle Scholar8.Leucker TM, Blaha MJ, Jones SR, Vavuranakis MA, Williams MS, Lai H, Schindler TH, Latina J, Schulman SP, Gerstenblith G. Effect of evolocumab on atherogenic lipoproteins during the peri- and early postinfarction period. Circulation. 2020;142:419–421. doi: 10.1161/CIRCULATIONAHA.120.046320CrossrefPubMedGoogle Scholar9.Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, et al; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute aoronary Syndrome. N Engl J Med. 2018;379:2097–2107. doi: 10.1056/NEJMoa1801174CrossrefPubMedGoogle Scholar10.Nicholls SJ, Kataoka Y, Nissen SE, Prati F, Windecker S, Puri R, Hucko T, Aradi D, Herrman J-PR, Hermanides RS, et al. Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction. JACC Cardiovasc Imaging. 2022;15:1308–1321. doi: 10.1016/j.jcmg.2022.03.002CrossrefPubMedGoogle Scholar11.Räber L, Ueki Y, Otsuka T, Losdat S, Häner JD, Lonborg J, Fahrni G, Iglesias JF, van Geuns R-J, Ondracek AS, et al; PACMAN-AMI collaborators. Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA. 2022;327:1771–1781. doi: 10.1001/jama.2022.5218CrossrefPubMedGoogle Scholar12.Cholesterol Treatment Trialists C. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681. doi: 10.1016/S0140-6736(10)61350-5CrossrefGoogle Scholar13.Raposeiras-Roubín S, Abu Assi E, Jiménez Méndez C, Mínguez de la Guía E, Pérez Rivera JA, Marcos Mangas M, Ayesta A, Uribarri A, Jorge Pérez P, Antúnez Muinos PJ, et al. Triple versus dual lipid-lowering therapy in acute coronary syndrome: the ES-BempedACS randomized clinical trial. Circulation. 2026;153:140–149. doi: 10.1161/CIRCULATIONAHA.125.075388CrossrefGoogle Scholar14.Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, Lalwani ND, Patel PM, Zhao X, Duell PB. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial. JAMA. 2019;322:1780–1788. doi: 10.1001/jama.2019.16585CrossrefPubMedGoogle Scholar15.Gao Y, Shah LM, Ding J, Martin SS. US trends in cholesterol screening, lipid levels, and lipid-lowering medication use in US adults, 1999 to 2018. J Am Heart Assoc. 2023;12:e028205. doi: 10.1161/JAHA.122.028205CrossrefPubMedGoogle ScholarShow all references
eLetterseLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article
Information & AuthorsInformationAuthorsInformationPublished In
CirculationVolume 153 • Number 3 • 20 January 2026Pages: 150 - 153PubMed: 41557782Copyright© 2026 American Heart Association, Inc.HistoryPublished online: 20 January 2026Published in print: 20 January 2026PermissionsRequest permissions for this article.Request permissionsKeywordsEditorialsacute coronary syndromeanticholesteremic agentsbempedoic acidcombination therapySubjectsSecondary PreventionAuthorsAffiliationsExpand AllJelani K. Grant, MD, MHS https://orcid.org/0000-0001-8034-2366Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins School of Medicine, Baltimore, MD (J.K.G., T.M.L.)Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD (J.K.G., T.M.L.).View all articles by this authorThorsten M. Leucker, MD, PhD https://orcid.org/0000-0003-2569-6617 tleucke1@jhmi.eduCiccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins School of Medicine, Baltimore, MD (J.K.G., T.M.L.)Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD (J.K.G., T.M.L.).View all articles by this authorNotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.For Disclosures, see page 153.Circulation is available at www.ahajournals.org/journal/circCorrespondence to: Thorsten M. Leucker, MD, PhD, 600 N Wolfe St, Johns Hopkins Hospital, Halsted 500, Baltimore, MD 21287. Email tleucke1@jhmi.eduDisclosuresJ.K.G has nothing to disclose. T.M.L. has received research grant support from Amgen, Novartis, and Merck.Metrics & CitationsMetricsCitationsMetrics
Article MetricsView all metricsDownloadsCitationsNo data available.05101520Jan 2026200TotalFirst 90 DaysTotal number of
downloads
See more details
Posted by 1 X users
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Please select your download format:
RIS (ProCite, Reference Manager)
EndNote
BibTex
Medlars
RefWorks
Direct Import
FiguresTablesMediaShareShareShare article linkhttps://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.125.077771Copy LinkCopied!Copying failed.ShareFacebookLinkedInX (formerly Twitter)emailWeChatBlueskyGet AccessGet Access
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login
Institutional Login
Email
Password
Forgot your password? Reset it
here
Keep me logged in
Login
Don’t have an account? Register
here
Save for later
Item saved, go to cart
Purchase Options
Purchase this article to access the full text.
Purchase access to this article for 24 hours
Reassessing the First Step: Lessons From ES-BempedACS and the Era of Multi-Mechanism LDL-C Lowering
Circulation
Vol. 153
No. 3
pp. 137-e20
USD
$35.00
Add to Cart
Checkout
Purchase access to this journal for 24 hours
Circulation
Vol. 153
No. 3
pp. 137-e20
USD
$40.00
Add to Cart
Checkout
Restore your content access
Enter your email address to restore your content access:
Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.
ReferencesReferencesReferences1.Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36:1163–1170. doi: 10.1093/eurheartj/ehu505CrossrefPubMedGoogle Scholar2.Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Covington AM, DePalma SM, Minissian MB, Orringer CE, Smith SC, Waring AA, et al; Writing Committee. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. J Am Coll Cardiol. 2022;80:1366–1418. doi: 10.1016/j.jacc.2022.07.006CrossrefPubMedGoogle Scholar3.Mach F, Koskinas KC, Roeters van Lennep JE, Tokgözoğlu L, Badimon L, Baigent C, Benn M, Binder CJ, Catapano AL, De Backer GG, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46:4359–4378. doi: 10.1093/eurheartj/ehaf190CrossrefPubMedGoogle Scholar4.Sarraju A, Yan X, Huang Q, Dudum R, Palaniappan L, Rodriguez F. Patterns and gaps in guideline-directed statin use for atherosclerotic cardiovascular disease by race and ethnicity. Am J Prev Cardiol. 2024;17:100647. doi: 10.1016/j.ajpc.2024.100647CrossrefPubMedGoogle Scholar5.Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–e1143. doi: 10.1161/CIR.0000000000000625CrossrefPubMedGoogle Scholar6.Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019;41:111–188. doi: 10.1093/eurheartj/ehz455CrossrefGoogle Scholar7.Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, et al; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–2397. doi: 10.1056/NEJMoa1410489CrossrefPubMedGoogle Scholar8.Leucker TM, Blaha MJ, Jones SR, Vavuranakis MA, Williams MS, Lai H, Schindler TH, Latina J, Schulman SP, Gerstenblith G. Effect of evolocumab on atherogenic lipoproteins during the peri- and early postinfarction period. Circulation. 2020;142:419–421. doi: 10.1161/CIRCULATIONAHA.120.046320CrossrefPubMedGoogle Scholar9.Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, et al; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute aoronary Syndrome. N Engl J Med. 2018;379:2097–2107. doi: 10.1056/NEJMoa1801174CrossrefPubMedGoogle Scholar10.Nicholls SJ, Kataoka Y, Nissen SE, Prati F, Windecker S, Puri R, Hucko T, Aradi D, Herrman J-PR, Hermanides RS, et al. Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction. JACC Cardiovasc Imaging. 2022;15:1308–1321. doi: 10.1016/j.jcmg.2022.03.002CrossrefPubMedGoogle Scholar11.Räber L, Ueki Y, Otsuka T, Losdat S, Häner JD, Lonborg J, Fahrni G, Iglesias JF, van Geuns R-J, Ondracek AS, et al; PACMAN-AMI collaborators. Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA. 2022;327:1771–1781. doi: 10.1001/jama.2022.5218CrossrefPubMedGoogle Scholar12.Cholesterol Treatment Trialists C. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681. doi: 10.1016/S0140-6736(10)61350-5CrossrefGoogle Scholar13.Raposeiras-Roubín S, Abu Assi E, Jiménez Méndez C, Mínguez de la Guía E, Pérez Rivera JA, Marcos Mangas M, Ayesta A, Uribarri A, Jorge Pérez P, Antúnez Muinos PJ, et al. Triple versus dual lipid-lowering therapy in acute coronary syndrome: the ES-BempedACS randomized clinical trial. Circulation. 2026;153:140–149. doi: 10.1161/CIRCULATIONAHA.125.075388CrossrefGoogle Scholar14.Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, Lalwani ND, Patel PM, Zhao X, Duell PB. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial. JAMA. 2019;322:1780–1788. doi: 10.1001/jama.2019.16585CrossrefPubMedGoogle Scholar15.Gao Y, Shah LM, Ding J, Martin SS. US trends in cholesterol screening, lipid levels, and lipid-lowering medication use in US adults, 1999 to 2018. J Am Heart Assoc. 2023;12:e028205. doi: 10.1161/JAHA.122.028205CrossrefPubMedGoogle Scholar
Advertisement
RecommendedNovember 2025Triple Versus Dual Lipid-Lowering Therapy in Acute Coronary Syndrome: The ES-BempedACS Randomized Clinical Trial
Sergio Raposeiras-Roubín,
Emad Abu Assi,
César Jiménez Méndez,
Ester Mínguez de la Guía,
José Ángel Pérez Rivera,
Marta Marcos Mangas,
Ana Ayesta,
Aitor Uribarri,
Pablo Jorge Pérez,
Pablo José Antúnez Muinos,
Clara Bonanad Lozano,
Anna Carrasquer,
Ana Viana-Tejedor,
Pablo Domínguez Erquicia,
Alberto Villar Ruiz,
Macarena López Vázquez,
Lara Aguilar Iglesias,
Alberto Alén Andrémar,
Maria Vidal Burdeus,
Marta Maria Martin Cabeza,
María Cristina González Cambeiro,
Daznia Bompart,
Juan Carlos Gómez Polo,
Marina Teresa García García,
Ana Merino Merino,
José Rozado,
José Antonio Panera de la Mano,
Francisco Salmerón Martínez,
Ester Sánchez Corral,
Isabel Santos Sánchez,
Ángel Víctor Hernández-Martos,
Andrés Antelo Abejón,
Andrés Iñiguez Romo,
Miguel Corbi-Pascual, and
[...]Albert Ariza-Solé
+31 authors
September 2022Network Meta‐Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid‐Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low‐Density Lipoprotein Cholesterol
Peter P. Toth,
Sarah Bray,
Guillermo Villa,
Tamara Palagashvili,
Naveed Sattar,
Erik S. G. Stroes, and
[...]Gavin M. Worth
+3 authors
January 2024LDL-C–Lowering Therapies for Adults and Children With Homozygous Familial Hypercholesterolemia: Challenges and Successes
Raul D. Santos and
[...]Marina Cuchel
+0 authors
Advertisement
Submit a Response to This ArticleCloseCompose eLetterTitle:Comment text:Contributors(all fields are required)Remove ContributorFirst Name:Last Name:Email:Affiliation:Add Another Contributor
Statement of Competing InterestsCompeting Interests?YESNOPlease describe the competing interests
CancelSubmitView full text|Download PDF
Comment Response
Circulation
Submit
Browse
Browse
Collections
Subject Terms
AHA Journal Podcasts
Trend Watch
Resources
Resources
CME
Journal Metrics
Early Career Resources
AHA Journals @ Meetings
Information
Information
For Authors
For Reviewers
For Subscribers
For International Users
Arteriosclerosis, Thrombosis, and Vascular Biology
Circulation
Circulation Research
Hypertension
Stroke
Journal of the American Heart Association
Circulation: Arrhythmia and Electrophysiology
Circulation: Cardiovascular Imaging
Circulation: Cardiovascular Interventions
Circulation: Population Health and Outcomes
Circulation: Genomic and Precision Medicine
Circulation: Heart Failure
Stroke: Vascular and Interventional Neurology
Annals of Internal Medicine: Clinical Cases
This page is managed by Wolters Kluwer Health, Inc. and/or its affiliates or subsidiaries. Wolters Kluwer Privacy Policy
Your California Privacy Choices
Manage Cookie Preferences
Back to top
National Center
7272 Greenville Ave.Dallas, TX 75231Customer Service
1-800-AHA-USA-1
1-800-242-8721Hours
Monday - Friday: 7 a.m. – 7 p.m. CT
Saturday: 9 a.m. - 5 p.m. CT
Closed on SundaysTax Identification Number
13-5613797
ABOUT
US
About the
AHA/ASA
Annual
report
AHA Financial
Information
Careers
International
Programs
Latest Heart and
Stroke News
AHA/ASA Media
Newsroom
GET
INVOLVED
Donate
Advocate
Volunteer
ShopHeart
ShopCPR
OUR
SITES
American Heart
Association
American Stroke
Association
CPR &
ECC
Go Red For
Women
More
Sites
AHA Careers
AHA Privacy Policy
Medical Advice Disclaimer
Copyright Policy
Accessibility Statement
Ethics Policy
Conflict of Interes Policy
Linking Policy
Whistleblower Policy
Content Editorial Guidelines
Diversity
Suppliers & Providers
State Fundraising Notices
©2026 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.The
American Heart Association is a qualified 501(c)(3) tax-exempt organization.*Red Dress ™ DHHS, Go Red ™
AHA ; National Wear Red Day® is a registered trademark.
Copy link✓Thanks for sharing!Find any serviceAddToAnyMore…Privacy Preference CenterWhen you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device. Because we respect your right to privacy, you can choose not to allow certain types of cookies on our website. Click on the different category headings to find out more and manage your cookie preferences. However, blocking some types of cookies may impact your experience on the site and the services we are able to offer.
Privacy & Cookie NoticeManage Consent PreferencesStrictly Necessary CookiesAlways ActiveThese cookies are necessary for the website to function. They are usually set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, this may have an effect on the proper functioning of (parts of) the site.View Vendor Details‎Functional Cookies
Functional Cookies These cookies enable the website to provide enhanced functionality, user experience and personalization, and may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies, then some or all of these services may not function properly.View Vendor Details‎Performance Cookies
Performance Cookies These cookies support analytic services that measure and improve the performance of our site. They
help us know which pages are the most and least popular and see how visitors move around the site.View Vendor Details‎Advertising Cookies
Advertising Cookies These cookies may collect insights to issue personalized content and advertising on our own and other websites, and may be set through our site by third party providers.
If you do not allow these cookies, you may still see basic advertising on your browser that is generic and not based on your interests.View Vendor Details‎Back ButtonVendors List Search IconFilter IconClear checkbox label labelApply CancelConsent Leg.Interest checkbox label label checkbox label label checkbox label labelAllow AllReject All Confirm My Choices
Now Reading:Reassessing the First Step: Lessons From ES-BempedACS and the Era of Multi-Mechanism LDL-C LoweringTrack CitationsAdd to favoritesShareGet AccessPREVIOUS ARTICLETriple Versus Dual Lipid-Lowering Therapy in Acute Coronary Syndrome: The ES-BempedACS Randomized Clinical TrialPreviousNEXT ARTICLESafety, Utility, and Outcomes of Procainamide Challenge for the Diagnosis and Exclusion of Brugada SyndromeNext__("articleCrossmark.closePopup")
